Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of HRS9531 in obesity with obstructive sleep apnea treated with PAP
CTR20252002Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in obesity, obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2025; status: active.
02
Drugs
HRS9531
03
Conditions
obesityobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on CTR20252002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252002.